NFE2L2 and renal cell carcinoma: Curiously, GSK-3β is generally overexpressed in RCC, where it supports tumor cells proliferation and it has been pointed out as a promising target for RCC treatment, with 9-ING-41 inhibitor in clinical trial [135], partially contrasting with the NRF2 accumulation and contribution to RCC progression.